



**Federal, State and Local Officials Gathered July 17th to Celebrate the First TETF Investment to an Abilene Company, Receptor Logic**

**Abilene, TX – July 18, 2008** - On Thursday, July 17th, top officials gathered at the Texas Tech University Health Sciences Center School of Pharmacy to celebrate the Texas Emerging Technology Fund investment of \$2 million the State gave to Receptor Logic, an Abilene-based biotech company. The TETF investment is the first to be received by a company located in Abilene.

The TETF investment is also the first to be made to a company founded on technology from Texas Tech University. Receptor Logic’s technology was developed at Texas Tech University by Dr. Jon Weidanz, Associate Professor School of Pharmacy, Texas Tech University Health Sciences Center in Abilene. Dr. Weidanz is also the Founder and Chief Scientist of Receptor Logic. Receptor Logic is funded and managed by Emergent Technologies, Inc., a life sciences venture firm focused on technology commercialization from Texas universities.

Gregory Pogue, Ph.D., President of Receptor Logic, said, “We appreciate the investment from the State not only for the recognition of the commercial viability of our technology, but also for the assistance it provides to accelerate Receptor Logic’s long-term growth and expansion plans. Our goal is to make a significant contribution to human healthcare through our TCRm technology and to fulfill a leadership role in biopharmaceutical advancement.”

Chief Executive Officer of the Development Corporation of Abilene (DCOA), Richard Burdine, added, “The TETF investment is a first for an Abilene-based company. The \$2 million will help Receptor Logic bring their innovative technology to the marketplace, and in so doing, provide valuable job and economic development opportunities for Abilene. It increases the future economic vitality of the whole West Texas region.”

David Miller, Vice-Chancellor of Technology Commercialization, Texas Tech University, said, “We greatly value this partnership and believe it will be instrumental in growing bio-tech research and commercialization in our region. Through this collaboration and funding announcement we will move this partnership forward to continue towards commercialization of this promising technology.”

In addition to Dr. Miller, other TTU officials attending the event included Kim Powell, Regional Dean and Associate Professor, Texas Tech University Health Sciences Center (TTUHSC) School of Pharmacy.

Local, state and federal officials who spoke at the Receptor Logic Press Briefing on July 17th included: Abilene Mayor Norm Archibald; Gregory Pogue, Ph.D., President and Managing Director, Receptor Logic; Jon Weidanz, Ph.D., Founder and Chief Scientist, Receptor Logic; Ryan Confer, Investment Manager, Texas Emerging Technology Fund; Joe Crawford, Board Chairman, Development Corporation of Abilene; David Miller, Texas Tech University System Vice-Chancellor of Technology Commercialization; State Senator Troy Fraser; and State Representative Susan King.

Receptor Logic will use the TETF investment to advance its efforts in the creation of antibodies through the company's T Cell Receptor mimic (TCRm™) technology. These TCRm's offer valuable insight into how the immune system interacts with a diseased cell, yielding better immunology research, better clinical diagnostics, and better therapies such as monoclonal antibodies and vaccines.

#### **About TTUS and the Office of Technology Commercialization**

The Texas Tech University System was created by the Higher Education Coordinating Board in 1996 to expand the educational and research opportunities offered to faculty and students by Texas Tech University and the Texas Tech University Health Sciences Center. Angelo State University joined the System in the summer of 2007.

The System's Office of Technology Commercialization works with university researchers to take their ideas, concepts and/or inventions to the marketplace. Miller and his team help to develop start-up companies, assemble an infrastructure to finance proof of concept funding and build relationships with external funding partners.

#### **About Receptor Logic, Inc.**

Receptor Logic, Inc. is a biopharmaceutical company specializing in high-quality antibodies that mimic the specificity of T Cell Receptors in the immune system. These T Cell Receptor mimics (TCRm) offer valuable insight into how the immune system interacts with a diseased cell, yielding better immunology research, better clinical diagnostics, and better therapies such as monoclonal antibodies and vaccines. Receptor Logic, Inc. is an Emergent Technologies Inc. (ETI) portfolio company, and ETI provides all management services. For more information, please visit the company website [www.receptor-logic.com](http://www.receptor-logic.com).

#### **About Emergent Technologies, Inc.**

Austin-based Emergent Technologies Inc. (ETI), founded in 1989 by Thomas A. Harlan, is a unique life sciences venture firm that forms and manages companies and funds that commercialize groundbreaking institutional and university-based technologies. ETI is a turnkey solution for converting university science into high return ventures. ETI works with regional economic development groups and universities to capitalize on the technology assets unique to their region. ETI is pioneering a unique business approach the firm describes as invention capital. In addition to the traditional venture capital approach of raising and investing funds, ETI drives the selection and expansion of each investment's intellectual property, the key asset to most technology-based start-up companies. For more information, please visit the company website [www.etibio.com](http://www.etibio.com)

###

Media Contact:

Sandra Oak  
Nsight Public Relations  
Phone: 321-591-1508  
Email: [soak@nsightpr.com](mailto:soak@nsightpr.com)